Evidence map›Paper›PMID 42044845›Full record

ArticleThe Journal of allergy and clinical immunology2026

CD25 expression marks an activated mast cell population in human nasal polyposis.

Rizza U Santos, Jada Suber, Tahereh Derakhshan, Sri Vidya Niharika Gullapalli, Kenshiro Matsuda, Mabel C Zawacki, Juying Lai, Regan W Bergmark, Stella E Lee, Alice Z Maxfield and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rizza U SantosDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass.
Jada SuberDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Tahereh DerakhshanDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Sri Vidya Niharika GullapalliDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Kenshiro MatsudaDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Mabel C ZawackiDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass.
Juying LaiDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass.
Regan W BergmarkHarvard Medical School, Boston, Mass; Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham, Boston, Mass.
Stella E LeeHarvard Medical School, Boston, Mass; Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham, Boston, Mass.
Alice Z MaxfieldHarvard Medical School, Boston, Mass; Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham, Boston, Mass.
Rachel E RoditiHarvard Medical School, Boston, Mass; Department of Otolaryngology-Head and Neck Surgery, Mass General Brigham, Boston, Mass.
Carolyn H BalohDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass; The Immune Tolerance Network, Benaroya Research Institute at Virginia Mason, Seattle, Wash.
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Joshua A BoyceDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass.
Daniel F DwyerDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Allergic Disease Research, Mass General Brigham, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: dfdwyer@bwh.harvard.edu.

Funding

Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2011 to 2026
$29.1M
Regulation of Pulmonary Prostaglandins by Leukotriene E4R01AI078908 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2009 to 2025
$8.8M
Eicosanoid Networks in Aspirin HypersensitivityR01AI136041 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2018 to 2026
$5.4M
CysLT and P2Y Receptors in Lung InflammationR37AI052353 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A · 2013 to 2022
$5.2M
Determining drivers of mast cell expansion and function during human airway diseaseR01HL174622 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel F Dwyer · 2024 to 2026
$2.1M
Patient-Oriented Research Mentorship and Training in Upper Airway Allergic and Inflammatory DiseasesK24AI180296 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Tanya Maria Laidlaw · 2024 to 2026
$522k
Defining Heterogeneous Human Mast Cell Effector FunctionR21AI180332 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DWYER, DANIEL F · 2024 to 2025
$492k
NHLBI NIH HHS R01 HL174622NIAID NIH HHS K24 AI180296NIAID NIH HHS R01 AI078908NIAID NIH HHS R01 AI136041NIAID NIH HHS R21 AI180332NIAID NIH HHS R37 AI052353NIAID NIH HHS U19 AI095219
6 · The paper itself

Abstract

backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a T

objectiveWe sought to use transcriptomics and flow cytometry to compare MC

methodsMC

resultsWe found a significant increase in MC

conclusionsOur data show that MC

Indexed as

Interleukin-2 Receptor alpha SubunitMast CellsNasal PolypsRhinosinusitisAdultChronic DiseaseFemaleHumansMaleMiddle AgedTryptasesIL2RA protein, humanInterleukin-2 Receptor alpha SubunitTryptasesCD25Chronic rhinosinusitisCRSsNPCRSwNPmast cellsRNA-seq

Identifiers

PMID42044845
PMCPMC13425570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.